SAI
NBIX icon

Savvy Advisors Inc’s Neurocrine Biosciences NBIX Stock Holding History

Savvy Advisors Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
+1,337
New +$198K ﹤0.01% 1127
2026
Q1 		– Sell
-2,374
Closed -$337K – 1195
2025
Q4 		$337K Buy
2,374
+650
+38% +$94.2K 0.01% 725
2025
Q3 		$242K Buy
+1,724
New +$234K 0.01% 713

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Savvy Advisors Inc's NBIX Position: Q2 2026 in Review

Savvy Advisors Inc opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,337 shares worth $225K. The stake represents ﹤0.01% of the portfolio and ranks #1127 among its holdings. This is a return to the name: Savvy Advisors Inc previously reported a position in NBIX as recently as Q4 2025.

Savvy Advisors Inc first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $337K in Q4 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Savvy Advisors Inc held 1,337 shares of Neurocrine Biosciences worth $225K as of Q2 2026.
  • Neurocrine Biosciences was a new Savvy Advisors Inc position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Savvy Advisors Inc's portfolio in Q2 2026, its #1127 holding.
  • Savvy Advisors Inc first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Savvy Advisors Inc's Neurocrine Biosciences position peaked at $337K in Q4 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Savvy Advisors Inc's 13F filing for Q2 2026, filed 3 Aug 2026.